“G-protein-coupled receptors are hot drug targets, and plenty of companies want to know what they look like to get an edge on making new drugs. Despite recent advances, getting X-ray crystal structures for GPCRs is still far from easy. Heptares Therapeutics, joins a trio of firms in licensing their structure-determining technology and partnering with large drugmakers to help push GPCR drug discovery forward. Heptares Therapeutics obtains GPCR X-ray structures with help from thermal stabilization – a targeted mutation technique developed by Chris Tate and Richard Henderson at LMB.” More…
Home > LMB In The News > Heptares Therapeutics helps push GPCR drug discovery forward